-
Patent Agency Ranking
公开(公告)号：US20250009871A1
公开(公告)日：2025-01-09
申请号：US18564932
申请日：2022-05-30
Applicant: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES , KUNMING INSTITUTE OF ZOOLOGY, CHINESE ACADEMY OF SCIENCES
Inventor： Likun GONG , Jin REN , Wei HUANG , Yong GAN , Yongtang ZHENG , Jianhua SUN , Xinxin ZHANG , Yiru LONG , Qiuping QIN , Tingting LIU , Feng TANG , Pan YU , Yunqiu MIAO , Yonglong CAI , Mian QIN , Tianzhang SONG
IPC: A61K39/215 , A61K9/107 , A61P37/04 , C07K14/005
Abstract: Disclosed are an application of a coronavirus SARS-CoV-2 vaccine polypeptide, a polypeptide composition and a nanoemulsion preparation thereof in the prevention of coronavirus SARS-CoV-2 wild and mutant strain infections. Specifically, provided is a coronavirus SARS-CoV-2 vaccine polypeptide having an amino acid sequence derived from an S protein of SARS-CoV-2 wild and mutant strains, the vaccine polypeptide can enable the body to generate high-level and durable humoral immune responses against SARS-CoV-2 and to produce high titers of RBD-binding antibodies and neutralizing antibodies that block the binding of RBD to ACE2. The vaccine polypeptide can be used to prevent infections of SARS-CoV-2 wild strain and B.1.1.7, B.1.351, B.1.617, B.1.1.529 and other mutant strains.
-
公开(公告)号：US20240197900A1
公开(公告)日：2024-06-20
申请号：US18278302
申请日：2022-02-22
Inventor： Wei HUANG , Feng TANG , Wei SHI , Shang JIAO , Siqi WANG
CPC classification number: A61K47/68031 , A61K47/68033 , A61K47/6883 , A61K47/6889 , A61P35/00 , C12N9/0006 , C12N9/2402 , C12P19/12 , C12Y101/03009 , C12Y302/01169
Abstract: The present application relates to a disaccharide linker, a disaccharide-small molecule drug conjugate and a sugar chain fixed-point antibody-drug conjugate, a preparation method and the use thereof. The structure of the disaccharide linker is as shown in the following formula I. The present invention provides a new-type fixed-point and quantitative antibody-drug conjugate form, and the stability and cytotoxicity of the antibody-drug conjugate are improved.
-
3.发明公开公开(公告)号：US20240261391A1
公开(公告)日：2024-08-08
申请号：US18565013
申请日：2022-05-30
Inventor： Xinxin ZHANG , Likun GONG , Jin REN , Guangyi JIN , Wei HUANG , Yong GAN , Jianhua SUN , Tingting LIU , Yiru LONG , Yunqiu MIAO , Qiuping QIN , Feng TANG , Pan YU , Linmiao GUO
IPC: A61K39/215 , A61K39/00 , A61K47/22 , C12N7/00
CPC classification number: A61K39/215 , A61K47/22 , C12N7/00 , A61K2039/55566 , C12N2770/20034
Abstract: The present invention relates to a novel coronavirus vaccine using a TLR7 agonist conjugated peptide as an antigen and an emulsion as an adjuvant. An antigen polypeptide of the conjugated peptide is a polypeptide derived from an S protein of SARS-COV-2, and the adjuvant is an oil-in-water nanoemulsion containing squalene. The conjugated peptide nanoemulsion vaccine preparation of the present invention is thermally stable, and can induce a high level of protective humoral immune response in a cynomolgus monkey, and the neutralizing antibody titer of antiserum after immunization of cynomolgus monkey is high, such that invasion of wild-type strain and mutant novel coronavirus can be blocked. The vaccine of the present invention has a nearly complete protection effect on the upper and lower respiratory tracts of the cynomolgus monkey in a cynomolgus monkey SARS-COV-2 challenge test. The nanoemulsion vaccine of the present invention is fast and convenient to prepare, and can realize large-scale production in a short term for coping with the novel coronavirus outbreak.
-
公开(公告)号：US20230338510A1
公开(公告)日：2023-10-26
申请号：US18010522
申请日：2021-06-11
Inventor： Likun GONG , Jin REN , Qiuping QIN , Weiliang ZHU , Yiru LONG , Zhijian XU , Jianhua SUN , Tingting LIU , Guangyi JIN , Jianping ZUO , Wei HUANG
IPC: A61P31/14 , A61K39/215 , A61K39/00
CPC classification number: A61K39/215 , A61K39/4611 , A61K39/4613 , A61K39/4614 , A61K39/4615 , A61K39/464838 , A61P31/14 , A61K2039/575 , A61K2039/70
Abstract: Provided are a tandem epitope polypeptide vaccine for novel coronavirus and use thereof. Specifically, a vaccine polypeptide for novel coronavirus pneumonia is provided on the basis of analysis and study of the RBD sequence and structural information of the S protein of SARS-CoV-2. Said vaccine polypeptide comprises the following elements connected in series: a generic Th epitope sequence, a B cell epitope sequence and a T cell epitope sequence. The B cell epitope and the T cell epitope have an amino acid sequence from the RBM region of the S protein of SARS-CoV-2. Provided are a vaccine composition containing said vaccine polypeptide and use thereof. Experiments show that the vaccine polypeptide of the present invention can enable cynomolgus monkeys to initiate strong cellular and humoral immunity, and to generate neutralizing antibodies that block the binding of RBD and ACE2, and can be used for preventing and treating novel coronavirus pneumonia.
-
公开(公告)号：US20230241204A1
公开(公告)日：2023-08-03
申请号：US18008826
申请日：2020-12-01
Inventor： Likun GONG , Jin REN , Guangyi JIN , Wei HUANG , Qiuping QIN , Yiru LONG , Jianhua SUN , Tingting LIU , Feng TANG , Peng ZHU
IPC: A61K39/215 , A61P31/14
CPC classification number: A61K39/215 , A61P31/14 , A61K2039/60
Abstract: Disclosed are a polypeptide vaccine coupled with a TLR7 agonist for novel coronavirus and the use thereof. Specifically, the present invention provides a vaccine polypeptide for novel coronavirus pneumonia based on the basis of the analytical study of the RBD sequence and structural information of the S protein of SARS-CoV-2, wherein the vaccine polypeptide has the following structural formula: Z-(J-U)n, where in the formula, Z, J, U, n, etc. are as defined in the description. Also provided in the present invention are a vaccine composition containing the vaccine polypeptide and the use thereof.
-
-
-
-
Search Results
5
records
(took 0.018 seconds)
